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Abstract
Background: Elevated plasma cholesterol promotes the formation of atherosclerotic lesions in which
monocyte-derived lipid-laden macrophages are frequently found. To analyze, if circulating monocytes
already show increased lipid content and differences in lipoprotein metabolism, we compared monocytes
from patients with Familial Hypercholesterolemia (FH) with those from healthy individuals.
Methods: Cholesterol and oxidized cholesterol metabolite serum levels of FH and of healthy, gender/age
matched control subjects were measured by combined gas chromatography – mass spectroscopy.
Monocytes from patients with FH and from healthy subjects were isolated by antibody-assisted density
centrifugation. Gene expression profiles of isolated monocytes were measured using Affymetrix HG-U
133 Plus 2.0 microarrays. We compared monocyte gene expression profiles from FH patients with healthy
controls using a Welch T-test with correction for multiple testing (p < 0.05; Benjamini Hochberg
correction, False Discovery Rate = 0.05). The differential expression of FH associated genes was validated
at the mRNA level by qRT-PCR and/or at the protein level by Western Blot or flow cytometry. Functional
validation of monocyte scavenger receptor activities were done by binding assays and dose/time
dependent uptake analysis using native and oxidized LDL.
Results: Using microarray analysis we found in FH patients a significant up-regulation of 1,617 genes and
a down-regulation of 701 genes compared to monocytes from healthy individuals. These include genes of
proteins that are involved in the uptake, biosynthesis, disposition, and cellular efflux of cholesterol. In
addition, plasma from FH patients contains elevated amounts of sterols and oxysterols. An increased
uptake of oxidized as well as of native LDL by FH monocytes combined with a down-regulation of NPC1
and ABCA1 explains the lipid accumulation observed in these cells.
Conclusion: Our data demonstrate that circulating FH monocytes show differences in cell physiology
that may contribute to the early onset of atherosclerosis in this disease.
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Background
Atherosclerosis is the primary cause of coronary heart dis-
ease (CHD) and stroke in Western societies [1]. It is char-
acterized by the development of lipid-rich lesions in the
arterial wall, in which foam cells, monocyte-derived lipid-
laden macrophages, are frequently found.
An important regulator of cellular cholesterol content is
the sterol regulatory element binding protein (SREBP)
pathway, which controls, by transcriptional regulation,
the uptake of cholesterol via LDL-receptor and several
steps in the de novo synthesis of cholesterol.
In healthy individuals cells ingest cholesterol by endocy-
tosis of LDL bound to the LDL-receptor (LDLR). After
endocytosis, the LDLR uncouples from its ligand and
returns to the cell surface, while the LDL is catabolized.
Cholesterol accumulation in membranes of the endoplas-
matic reticulum (ER) results in a down-regulation of the
SREBP pathway and subsequently in the repression of 3-
hydroxy-3-methyl-glutaryl-CoA-reductase (Hmgcr), the
rate limiting enzyme of the de novo cholesterol biosynthe-
sis [2]. Efflux of excessive cholesterol is mediated by
Abca1, the major cholesterol efflux system in macro-
phages, which transfers cholesterol to apolipoprotein A1
on HDL particles. It is assumed that Npc1 has a pivotal
role in cholesterol efflux as it aids in the cellular distribu-
tion of lysosomal cholesterol which enables Abca1
dependent efflux [3,4].
In contrast to native LDL, macrophages utilize scavenger
receptors (SR), such as CD36, for the uptake of modified
LDL [5]. Several studies have demonstrated that macro-
phages express high levels of CD36 enabling them to bind
and internalize oxidized lipoproteins. It is well estab-
lished that oxidized LDL (oxLDL) is cytotoxic and that it
has the ability to induce apoptosis. As oxLDL is frequently
found in atherosclerotic lesions it is assumed that its accu-
mulation contributes to the pathogenesis of atherosclero-
sis [5]. Therefore, a rapid clearance of oxLDL deposits
from the arterial wall via SRs by monocyte derived macro-
phages is essential for atherosclerosis prevention.
However, only few data exist on the involvement of circu-
lating monocytes in this pathologic process in men [6]. To
date, studies of atherosclerosis development have been
carried out mostly in pathologic human specimen, cell
lines, and primary cell culture systems, as well as in ani-
mal models [5]. To study monocyte function in a hyperli-
pidemic environment in men we examined patients
suffering from the monogenic disorder Familial Hyperc-
holesterolemia (FH). FH patients have a defective or miss-
ing LDLR which results in dramatically elevated plasma
LDL-cholesterol levels and early onset of atherosclerosis.
Further, atherosclerosis progression in FH is mainly inde-
pendent from the presence of additional genetic and envi-
ronmental risk factors [7] which makes it a suitable model
trait for studying human atherosclerosis.
Methods
Participants
Homozygous and heterozygous FH patients with docu-
mented genetic defects in the LDL receptor (LDLR) gene
and healthy volunteers were informed about the aim of
the study and gave written informed consent. The study
was approved by the Ethics Committee of the Friedrich
Schiller University of Jena/Germany. All homozygous FH
patients were treated with haemapheresis. In addition,
three of eight homozygous patients also received statin
treatment. Of the heterozygous patients three received
neither statin nor apheresis therapy. Five heterozygous
patients received apheresis as well as statin therapy. Those
patients who did not receive statin treatment did not
show a significant response in their plasma cholesterol
levels to the drug treatment. (FH patients: LDLR muta-
tions given in Table 4).
Cell isolation, cryopreservation and cell culture
For microarray analysis and cell culture assays cells were
isolated with RosetteSep Monocyte Enrichment Cocktail
(Cell Systems, St. Katharinen, Germany) according to the
manufacturer's protocol. Cell purity was analyzed by flow
cytometry with antibodies directed against CD14 (mono-
cytes), CD3 (T cells), CD235a (erythrocytes), CD19 (B
cells), and CD56 (NK cells). All cell preparations had a
purity of > 95%. The viability of cells was checked by
staining with 7-amino-actinomycin D (7-AAD) (Becton
Dickinson, Heidelberg, Germany). The number of 7-AAD
positive cells was below 3% in all preparations. In addi-
tion, the viability of monocytes was confirmed by their
inflammatory response to LPS (Sigma-Aldrich, Munich,
Germany) stimulation (data not shown).
For cell culture assays, isolated monocytes were resus-
pended in 10% DMSO (Sigma-Aldrich, Munich, Ger-
many), 60% IMDM (Invitrogen, Karlsruhe, Germany),
and 30% autologous serum. They were then frozen with a
temperature decline of -1°C/min to -80°C, and stored in
liquid nitrogen. Frozen cells were thawed at 37°C, washed
twice with PBS/2 mM EDTA and resuspended in X-VIVO
15 (Cambrex, Walkersville, USA). For all binding, uptake
and blocking assays 1 × 105 monocytes per well were cul-
tured in X-VIVO 15 serum free medium with the indicated
concentrations of nLDL, oxLDL, and antibodies.
Monocyte to macrophage differentiation was carried out
by culturing cryopreserved monocytes for 10 days in X-
VIVO 15 medium (Lonza, Walkersville, MD) with addi-
tion of 10% of human serum from a healthy, normolipi-
demic donor.BMC Medical Genomics 2008, 1:60 http://www.biomedcentral.com/1755-8794/1/60
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Microarray analysis
Freshly isolated cells were lysed in TRIZOL (Invitrogen,
Karlsruhe, Germany). RNA was extracted using the RNe-
asy Micro Kit (Qiagen, Hilden, Germany). RNA was quan-
tified using a Nanodrop photometer (Thermo Scientific,
Wilmington, Delaware, USA). RNA quality was measured
with an Agilent 2100 Bioanalyzer using the RNA Nano kit
(Agilent Technologies, Waldbronn, Germany). Only RNA
with a RNA integrity number better than 9.5 was used for
microarrays. 1 μg of total RNA was processed with
Affymetrix One-Cycle Target Labeling Control reagents
and hybridized to Affymetrix HG U133 Plus 2.0 Gene-
Chip Arrays. Raw data were obtained with Affymetrix
GCOS 1.3. Quality control of microarray raw data was
done with the Bioconductor "affyQCReport" R package
including Whisker box plots, density plots, plotting of 3'/
5' ratios of GAPDH and beta-actin, scaling factor and
background noise, and correlation plots of all microarrays
(Supplementary Figure 1). Raw data were imported to
GeneSpring GX 7.3.1 (Agilent Technologies) using the
RMA (Robust Multi-Array Average) algorithm [8]. They
were normalized per chip to the 50th percentile and per
gene to the median. Transcripts with a raw data value of
20 and more in at least half of all measured arrays were
considered as "expressed". 35.264 transcripts fulfilled this
criterion. Functional annotation clustering was performed
with DAVID 2008 http://david.abcc.ncifcrf.gov. The
resulting group enrichment score represents the negative
logarithm of the geometric mean of Fisher's exact test p-
values from cluster members [9,10]. Pathway analysis was
done with the Agilent Pathway Architect (Agilent, Wald-
bronn, Germany).
Microarray data samples were deposited in the Gene
Expression Omnibus database http://
www.ncbi.nlm.nih.gov/geo. They are accessible under the
series GSE6054.
Quantitative Real-time PCR
Quantitative Real-time PCR (qRT-PCR) was performed
using the Eppendorf RealPlex 2S PCR (Eppendorf, Ham-
burg, Germany) and QuantiTect Primer Assays (Qiagen,
Hilden, Germany). Quantification was done using stand-
ards with known copy numbers and normalization to
ubiquitin C (UBC).
LDL-isolation, preparation and labelling
LDL were isolated from fresh serum of normolipidemic
donors by sequential ultracentrifugation [11] and stored
in 0.02% NaN3, Na2EDTA (0.24 mM) at 4°C overlaid
with nitrogen. Preparations were used within two weeks.
Oxidation of LDL was achieved by a 6 hour incubation of
native LDL with 10 μM CuSO4 at 37°C. Oxidized LDL was
desalted by PD-10 Desalting columns from GE Healthcare
(Uppsala, Sweden) and eluted in PBS.
nLDL and oxLDL were labelled using the Alexa-Fluor488-
and Alexa-Fluor647-Protein labelling kits (Molecular
Probes, Leiden, Netherlands) according to the manufac-
turer's protocols. All LDL forms were endotoxin-low (<
0.02 EU/ml), tested by QCL-1000 Chromogenic LAL
(Cambrex, Walkersville, USA). The OxLDL ELISA-Kit was
obtained from Immundiagnostik AG (Bensheim, Ger-
many). LDL protein content was measured by a modified
Lowry protein assay (Biorad, Hercules, USA).
Oil red O staining
105 monocytes/well were seeded and adhered to cover-
slips (Nalge Nunc International, Rochester, USA) in X-
VIVO 15 for 4 hours. After adhesion, cells were washed
twice with PBS/2 mM EDTA and once with PBS. They were
then fixed using 4% paraformaldehyd for 10 minutes,
rinsed with 60% isopropanol, incubated for 10 minutes
with Oil Red O, rinsed again with isopropanol, and
washed with aqua dest. After hematoxylin-incubation and
-oxidation coverslips were rinsed again and were imbed-
ded in aqueous mounting medium. Images have been
taken on Zeiss AxioVert200M (Carl Zeiss, Jena, Germany).
Plasma-concentrations of sterols
10  μg/ml butylhydroxytoluol (Sigma Aldrich, Munich,
Germany) were added to fresh plasma of donors which
was subsequently frozen and stored at -80°C until analy-
sis. Serum concentrations of cholesterol were measured by
gas chromatography-flame ionization detection using
5alpha-cholestane as internal standard and cholesterol
precursors and plant sterols by gas chromatography-mass
spectrometry with epicoprostanol as internal standard.
Oxidized cholesterol metabolites (7α-, 24S- and 27-
hydroxycholesterol) were analyzed using an isotope dilu-
tion method and quantified by selected ion monitoring
gas chromatography-mass spectrometry [12].
Time and dose dependency, binding and blocking 
experiments
For uptake studies monocytes were washed as described
above and incubated with LDL for the indicated times at
37°C, 5% CO2. Binding studies were performed at 4°C.
CD36 and Lrp1 blocking was done with 10 μg/ml murine
IgG (MOPC-21) (Abcam, Cambridge, UK), rabbit IgG
(Innovative Research, Southfield, USA), anti-human
CD36 (FA6-152) (Abcam, Cambridge, UK) or anti-
human Lrp1 (Biomac, Leipzig, Germany) for 30 minutes
at 37°C, 5% CO2 and incubated with the indicated LDL
forms for 4 hours at 37°C, 5% CO2. All antibodies used
were endotoxin-low and azide-free.
Flow cytometry
Purity control antibodies, isotype control antibodies and
anti-CD36 were from ImmunoTools (Friesoythe, Ger-
many). Anti-CD91 was from BD Biosciences (Heidelberg,BMC Medical Genomics 2008, 1:60 http://www.biomedcentral.com/1755-8794/1/60
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Germany). Flow cytometry has been performed on a FAC-
SCalibur (Becton Dickinson, Heidelberg, Germany) and
data analyzed with FlowJo 7.2.2. (TreeStar, Ashland, OR,
USA).
Western Blots
1 × 106 monocytes were lysed in lysis buffer (50 mM
TrisCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% NP-40,
protease inhibitors). Protein content was measured using
BCA-Protein-Assay Kit (Pierce, Rockford, USA). 10 μg pro-
tein/individual were subjected to SDS-PAGE and Western
Blotting. Primary antibodies against β-Actin (Cell Signal-
ing, Danvers, USA), ABCA1 (Novus Biologicals, Littleton,
USA), SCAP, NPC1 (Santa Cruz Biotechnology, Heidel-
berg, Germany), CD36 (FA6-152) (Abcam, Cambridge,
UK) and Lrp1 (R2629, kindly provided by DK Strickland)
were used. Secondary horseradish-peroxidase conjugated
goat anti-mouse, rabbit anti-goat and goat anti-rabbit
antibodies were purchased from KPL (Gaithersburg,
USA). ECL was from Perkin Elmer (Boston, USA).
Statistical analyses
Statistical analyses were performed with SPSS 14.0 (SPSS,
Chicago, USA) using two-sided Students t-Test, if not oth-
erwise indicated. Error bars indicate the standard devia-
tion.
Results
At first we measured plasma oxLDL levels of FH patients
and healthy controls using ELISA, which were signifi-
cantly increased in homozygous FH patients (Figure 1A,
baseline characteristics given in Table 1). OxLDL levels in
the plasma of heterozygous patients were not different
from those of the control individuals. We also analyzed
the plasma of FH patients and controls for sterols, includ-
ing phyto- and oxysterols. All tested sterols, except the
cholesterol biosynthesis intermediates lathosterol and
lanosterol were significantly elevated in homozygous FH
patients (Table 2). We then analyzed, if there were differ-
ences in the lipid content of monocytes from
homozygous or heterozygous FH patients and controls
using Oil Red O staining. Figures 1B, C [see Additional file
1] show that the number of Oil Red O positive cells is sig-
nificantly higher in homozygous FH patients than in
healthy donors, which may indicate an increased lipid
content of FH monocytes. Heterozygous FH patients
showed a slight increase in Oil Red O positive cells, how-
ever their number is not significantly different from those
of control subjects. Although it would have been very
interesting to directly measure intracellular cholesterol
content limited amounts of sample material did not allow
us to do the measurements. To identify potential sources
of intracellular cholesterol we carried out LDL binding
and LDL uptake studies and measured the binding of
native LDL (nLDL) and oxidized LDL (oxLDL) (labelled
with Alexa Fluor 488) after 1 hour incubation at 4°C
using cryopreserved monocytes from FH patients and con-
trol individuals. Binding specificity was confirmed by a
chase with a 50-fold excess of unlabelled LDL (data not
shown). The binding capacity for oxLDL to homozygous
FH monocytes was higher than in heterozygous FH
monocytes and controls. The binding capacity for the lat-
ter ones was very similar (Figure 2A). Surprisingly, no
binding difference was seen for nLDL (Figure 2B). Uptake
studies for 1 hour at 37°C with 50 μg/ml to 200 μg/ml
nLDL and oxLDL, respectively, demonstrate a significantly
increased uptake of oxLDL in homozygous FH monocytes
(Figure 2C). Again there was no difference between the
monocytes of heterozygous FH patients and controls. For
uptake of nLDL we found no differences between all three
groups (Figure 2D). The most prominent difference
between FH and control monocytes was observed at 100
μg/ml oxLDL. This concentration was subsequently used
to study the time dependent uptake of oxLDL and nLDL
for up to 4 hours. At the 4 hour time-point the amounts
of both, oxLDL and nLDL, incorporated in monocytes
were significantly higher in cells from homozygous FH
patients than in those from heterozygous FH patients or
from controls (Figure 2E and 2F).
As FH monocytes show a clearly increased uptake of LDL
and concomitantly FH carriers have significantly
increased serum oxLDL levels, we analyzed the cellular
Serum oxLDL levels and neutral lipid content of monocytes  from FH patients and healthy individuals Figure 1
Serum oxLDL levels and neutral lipid content of 
monocytes from FH patients and healthy individuals. 
A: Serum oxLDL concentrations of homo- and heterozygous 
FH patients and controls (homozygous FH n = 8, hetero-
zygous FH n = 8, controls n = 19). B, C: Monocytes from con-
trols and homozygous FH patients were stained with Oil Red 
O to visualize neutral lipid content. B: Representative stain-
ings are shown. C: Histogram of percentage of Oil Red O 
positive monocytes of FH patients and controls. Monocytes 
of 15 randomly taken pictures were counted, > 200 mono-
cytes/person (FH homozygous n = 3, controls n = 4). Histo-
gram bars indicate the mean ± SD, (* p < 0.05).BMC Medical Genomics 2008, 1:60 http://www.biomedcentral.com/1755-8794/1/60
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LDL binding and uptake characteristics of monocytes of FH patients and healthy donors Figure 2
LDL binding and uptake characteristics of monocytes of FH patients and healthy donors. A-E: Binding and uptake 
of oxidized LDL (homozygous FH (black triangles) n = 4, heterozygous FH (gray triangles) n = 4 and healthy controls (open tri-
angles) n = 4) and native LDL (homozygous FH (black circles) n = 4, heterozygous FH (gray circles), healthy controls (open cir-
cles) n = 4) by monocytes. A: Binding of AF488 labelled oxLDL and B: nLDL for 1 h at 4°C. C: Dose dependent uptake of AF488 
labelled oxLDL and D: nLDL for 1 h at 37°C. E: Time dependent uptake of 100 μg/ml AF488 labelled oxLDL and E: nLDL for up 
to 4 h; please note that due to separate lipoprotein preparations for each experiment fluorescence intensities cannot be com-
pared between subpanels A-E; comparison is only possible within a subpanel; experiments were done in duplicate; histogram 
bars indicate the mean ± SD (* p < 0.05, ** p < 0.01).BMC Medical Genomics 2008, 1:60 http://www.biomedcentral.com/1755-8794/1/60
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response to the higher uptake of cholesterol in FH mono-
cytes using microarray analysis (quality control data [see
Additional file 2]). The transcriptomes of freshly isolated
monocytes from FH patients (baseline characteristics are
given in Table 1) were analyzed using Affymetrix HG133
Plus 2.0 microarrays. 35,264 transcripts in monocytes that
fulfilled the threshold criteria for expressed genes (a raw
expression value of at least 20 in half of all measured array
was considered as "expressed") were analyzed by princi-
pal component analysis (PCA). Gene expression profiles
of monocytes from FH patients and from controls were
clearly separated from each other (Figure 3). A Welch T
test with correction for multiple testing (p < 0.05; Ben-
jamini Hochberg correction, False Discovery Rate = 0.05)
showed that 2,318 genes in monocytes were differently
expressed. Of these genes 1,617 were up-regulated and
701 were down-regulated in monocytes of FH patients.
Using DAVID 2008, a web based tool for functional anno-
tation clustering [9], we identified among regulated tran-
scripts functional clusters of genes coding for proteins
involved in 1) intracellular protein transport, 2) clathrin
coated vesicle transport, 3) lysosome and lytic vacuole, 4)
regulation of JNK activity and 5) endocytosis (Table 3).
These data and the observed increased uptake of nLDL
and oxLDL by FH monocytes point to differences in LDL
uptake that could involve scavenger receptors, as a role for
CD36 and LRP1 has been reported for oxLDL and nLDL
uptake in macrophages, respectively. Further, a pathway
Table 1: Baseline characteristics and lipid levels of the study group.
homozygous FH heterozygous FH Controls
Gender female n = 6 female n = 5 female n = 16
male n = 2 male n = 3 male n = 10
Age (years) 30.2 ± 11.1 28.8 ± 7.5 33.8 ± 11.2
LDL (mg/dl) 413.82 ± 92.33 (***) 220.64 ± 27.81 (***) 107.03 ± 17.78
HDL (mg/dl) 60.33 ± 8.09 54.17 ± 3.71 61.17 ± 6.60
Triglycerides (mg/dl) 141.31 ± 39.89 233.61 ± 132.80 107.63 ± 33.04
Lp(a) (mg/dl) 676.67 ± 347.06 442.73 ± 420.11 187.53 ± 153.59
Leukocytes (Gpt/l) 7.64 ± 0.95 5.45 ± 0.57 6.38 ± 0.8
Thrombocytes (Gpt/l) 253.12 ± 22.2 277.39 ± 37.51 258.12 ± 21.97
Values are means ± SD. FH, familial hypercholesterolemia; Gpt, Giga particles; Tpt, Terra particles.
Table 2: Plasma concentrations of sterols and sterol to plasma-cholesterol ratio of homozygous and heterozygous FH patients and 
controls.
homozygous FH (n = 5) heterozygous FH (n = 5) Controls (n = 8)
plasma conc. sterol: Cholesterol plasma conc. sterol: Cholesterol plasma conc. sterol: Cholesterol
Cholestanol (mg/dl) 0.608 ± 0.075 (***) 1,60*10-3 : 1 0.442 ± 0.062 (*) 1,73*10-3 : 1 0.278 ± 0.038 1,59*10-3 : 1
Lathosterol (mg/dl) 0.725 ± 0.226 1,78*10-3 : 1 0.563 ± 0.182 1,85*10-3 : 1 0.335 ± 0.121 1,61*10-3 : 1
Campesterol 
(mg/dl)
0.692 ± 0.17 (**) 1,77*10-3 : 1 0.651 ± 0.243 (*) 2.58*10-3 : 1 0.267 ± 0.031 1.40*10-3 : 1
Campestanol (μg/
dl)
4.773 ± 1.096 (**) 1,23*10-5 : 1 5.237 ± 1.402 (**) 2.09*10-5 : 1 2.151 ± 0.253 1.37*10-5 : 1
Stigmasterol (μg/
dl)
24.805 ± 7.533 (**) 6.54*10-5 : 1 19.163 ± 6.081 (*) 7.79*10-5 : 1 7.772 ± 1.84 4.25*10-5 : 1
Sitosterol (mg/dl) 0.522 ± 0.103 (**) 1.37*10-3 : 1 0.519 ± 0.161 (*) 2.08*10-3 : 1 0.184 ± 0.035 1.06*10-3 : 1
Sitostanol (μg/dl) 8.597 ± 2.603 (*) 2.13*10-5 : 1 7.206 ± 2.261 (*) 2.76*10-5 : 1 2.933 ± 0.625 1.96*10-5 : 1
Brassicosterol (μg/
dl)
84.004 ± 17.864 (**) 2.18*10-4 : 1 80.706 ± 26.213 (*) 3.15*10-4 : 1 29.173 ± 2.612 1.88*10-4 : 1
Lanosterol (μg/dl) 39.812 ± 8.347 1.01*10-4 : 1 (**) 34.568 ± 12.712 1.23*10-4 : 1 31.123 ± 5.523 1.79*10-4 : 1
Desmosterol 
(mg/dl)
0.359 ± 0.045 (**) 9.37*10-4 : 1 0.254 ± 0.046 9.54*10-4 : 1 0.167 ± 0.034 9.62*10-4 : 1
24OH-Cholesterol 
(ng/ml)
87.820 ± 18.094 (*) 2.26*10-7 : 1 74.078 ± 9.541 2.90*10-7 : 1 50.585 ± 9.936 3.02*10-7 : 1
27OH-Cholesterol 
(ng/ml)
196.463 ± 27.528 (**) 5.12*10-7 : 1 179.638 ± 19. 015 (*) 6.98*10-7 : 1 49.95 ± 9.533 7.75*10-7 : 1
7αOH-Cholesterol 
(ng/ml)
142.908 ± 49.165 (*) 3.95*10-7 : 1 63.429 ± 10.802 2.43*10-7 : 1 47.363 8.812 3.02*10-7 : 1
Cholesterol (mg/dl) 385,748 ± 50.41 (***) 260.55 ± 22.070 (*) 165.669 ± 31.263
Values are means ± SD. FH, familial hypercholesterolemia.BMC Medical Genomics 2008, 1:60 http://www.biomedcentral.com/1755-8794/1/60
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analysis of the differentially expressed genes showed that
the SAPK-JNK, p38 and MAPK pathways belong to the
most prominently regulated signaling pathways in FH
monocytes. Recent publications have shown that these
signaling pathways are crucial for the development of
atherosclerosis and are regulated by oxLDL in a scavenger
receptor dependent manner [13,14]. Also among the top
5 regulated signaling pathways are the apoptosis and the
death receptor pathways, which are both down-regulated.
Our data thus support recently published work from
Namgaladze et al. who demonstrated that oxLDL can
attenuate apoptosis in monocytes [15]. Further, also the
VEGF signalling pathway is up-regulated in FH mono-
cytes. Interestingly there is a recent publication reporting
that C-reactive protein (CRP), a suggested independent
risk marker of atherosclerosis, induces VEGF expression
via Erk/PI3K signalling. Expression of these signalling
pathways is also increased in FH monocytes [16].
An analysis of the gene expression profiles of FH mono-
cytes revealed an up-regulation of CD36 and LRP1 which
was confirmed by qRT-PCR [see Additional file 3]. Using
flow cytometry, we demonstrated that also the protein
expression of both receptors was increased in FH mono-
cytes (Figure 4A). The elevated protein expression of Lrp1
in homozygous FH monocytes was also verified by West-
ern Blot (Figure 4B [see Additional File 4]). CD36 which
plays a major role for the acquisition of excess cellular
cholesterol in tissue macrophages in mice [17] was tested
for its contribution to the increased uptake of oxLDL and
nLDL by FH monocytes. Using a CD36 blocking antibody
we found a reduction of oxLDL uptake in homozygous as
well as heterozygous FH monocytes by more than 50 per-
cent (Figure 4C [see Additional file 4]). OxLDL uptake was
also reduced in monocytes of healthy controls by block-
ing CD36. However, monocytes of FH patients took up
much more oxLDL via CD36 compared to healthy con-
trols. In contrast to oxLDL uptake, a role of CD36 in the
uptake of nLDL was excluded (data not shown). To test
whether Lrp1 has a function in nLDL uptake of monocytes
we performed experiments with a blocking antibody
against Lrp1. As shown in Figure 4D [see Additional file 4]
Lrp1 blocking did not result in any change of the uptake
of nLDL in either FH or control monocytes.
Npc1 and Abca1 have been identified as crucial for the
distribution and secretion of cholesterol within macro-
phages [18,19]. We therefore analyzed the expression of
these two genes in FH monocytes and found the expres-
sion of both, NPC1 and ABCA1 mRNAs down-regulated
in FH on microarrays. Using qRT-PCR we verified the
reduced expression of NPC1 (Figure 5A). Also the protein
expression of NPC1 and ABCA1 was found reduced in
homozygous FH (Figure 5B [see Additional file 5]). This
was further verified in monocytes differentiated to macro-
phages in cell culture using GAPDH as an internal stand-
ard. Although ABCA1 mRNA concentration increased
during the differentiation process the relative fold change
of ABCA1 expression is markedly smaller in monocyte
derived macrophages of homozygous FH patients com-
pared to those from control subjects (Figure 5 [see Addi-
tional file 5]). It is thus likely that the lipid overload of FH
monocytes observed by Oil Red O staining results from
both, an increased oxLDL and nLDL uptake and a reduced
cellular efflux.
We also measured the expression of genes responsible for
cholesterol  de-novo  synthesis of the SREBP pathway,
which regulates the cellular cholesterol content. The anal-
ysis of gene expression profiles revealed that most SREBP
pathway genes were down-regulated in FH monocytes. In
addition, both, quantitative real-time PCR (qRT-PCR) and
Western blotting exhibited a significantly reduced expres-
sion of INSIG2, SREBF2 and SCAP (Figure 6A and Figure
6B, C [see Additional file 6]). Moreover, the gene for the
key regulating enzyme of cholesterol de novo synthesis,
HMGCR, and the LDLR were expressed at lower levels in
FH than in control monocytes (Figure 6D [see Additional
file 6] and data not shown). The SREBP pathway is also
down regulated in monocytes from heterozygous FH
patients. As in both, FH monocytes and control mono-
cytes LDL uptake increases with rising concentrations of
Principal component analysis (PCA) of gene expression pro- files from monocytes Figure 3
Principal component analysis (PCA) of gene expres-
sion profiles from monocytes. PCA of 35,264 transcripts 
expressed in monocytes of homozygous FH patients (filled 
circles), heterozygous FH patients (grey filled circles) and 
controls (open circles), respectively, that passed pre-filter 
criteria (described in Material and Methods). Gene signatures 
in monocytes from FH patients are sufficient to distinguish 
between FH and healthy controls.
0
1
0
1
0
1
0
1
Z: PCA component 3 (5,363% variance)
0
1
0
1
X: PCA component 1 (46,71% variance)
Y: PCA component 2 (8,327% variance)BMC Medical Genomics 2008, 1:60 http://www.biomedcentral.com/1755-8794/1/60
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LDL in the cell culture, we assume that this concentration
dependence in LDL uptake also occurs in vivo. Hence,
monocytes freshly isolated from heterozygous FH
patients, who have significantly elevated serum LDL lev-
els, have likely taken up more LDL during circulation
which is expected to result in a down regulation of choles-
terol sensitive SREBP pathway genes. The observed down-
regulation of the SREBP pathway is not expected to be
caused by medication as both, FH patients receiving med-
ication as well as FH patients without medication, show a
similar reduction in SREBP gene expression [see Addi-
tional file 7].
We also found the intracellular levels of lanosterol, a pre-
cursor in the de-novo cholesterol biosynthesis, reduced by
about 50% in monocytes from homozygous FH patients
(control monocytes: 0.019887 μg lanosterol/mg cellular
dry weight; FH monocytes: 0.0100980 μg lanosterol/mg
cellular dry weight; p < 0.05). Taken together, these data
argue for a down-regulation of the SREBP-pathway due to
an elevated uptake of nLDL by an unknown mechanism
and oxLDL via CD36 resulting in a cellular cholesterol
overload of FH monocytes.
Conclusion
An important role of macrophages in arterial wall metab-
olism and in the pathogenesis of atherosclerosis is well
documented [1]. We were interested to see, if already their
precursors in the bloodstream, the monocytes possess an
increased lipid content. Oil Red O staining of freshly iso-
lated monocytes revealed that FH monocytes have higher
lipid content than control monocytes. They also show an
increased uptake of nLDL and oxLDL. This and the three
to fourfold higher plasma concentrations of oxLDL and
nLDL in FH patients can explain the observed higher
number of lipid-laden monocytes in FH. Our data is in
agreement with recent reports from LDLR deficient mice
which have an increased intracellular cholesterol content
in macrophages [20].
Table 3: Functional cluster analysis of differentially regulated genes in monocytes between FH individuals and controls.
Welch T-Test 
(p < 0.05, Benjamini Hochberg Testing 
Correction FDR = 0.05)
Functional GO cluster Genes Group Enrichment Score
2,318 transcripts regulated protein transport, establishment of protein localization, 
intracellular protein transport
130 7.62
clathrin coated vesicle, trans Golgi network transport 
vesicle, Golgi associated vesicle membrane, transport vesicle 
membrane
15 2.86
vacuole, lysosome, lytic vacuole 37 2.42
regulation of JNK activity activation of JNK activity,, positive 
activation of JNK activity, activation of MAPK activity
14 2.32
clathrin coated endocytotic vesicle, AP-2 adaptor complex, 
endocytotic vesicle membrane
42 . 0 0
Table 4: Individual LDL-R characteristics of each FH patient those monocytes where analyzed by microarray.
homozygous FH Mutation
Patient 1 C88R (FH Münster 1), D333G (FH Münster 2); < 5% LDL-R activity, binding defect
Patient 2 W556R; < 5% receptor activity (class 2A)
Patient 3 W556R; < 5% receptor activity (class 2A)
Patient 4 W556R; < 5% receptor activity (class 2A)
Patient 5 LDL-R binding defect demonstrated by fibroblast LDL binding assay
Patient 6–8 Diagnosis based on clinical parameters according to the Simon Broome Register Group criteria 
(xanthomas, lipid profile, familial history)
heterozygous FH
Patient 9 promoter defect -135 bp C->G, 5–15% activity
Patient 10 C88R (FH Münster 1), 15–30% receptor activity binding defect
Patient 11 D333G (FH Münster 2), 15–30% receptor activity binding defect
Patient 12 C88R (FH Münster 1), 15–30% receptor activity binding defect
Patient 13 LDL-R binding defect demonstrated by fibroblast LDL binding assay
Patient 14 W556R; < 5% receptor activity (class 2A)
Patient 15 insertion of G at 588 bp -> STOP at codon 178
Patients 16 insertion of G at 588 bp -> STOP at codon 178BMC Medical Genomics 2008, 1:60 http://www.biomedcentral.com/1755-8794/1/60
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To assess the consequences of the intracellular lipid
enrichment in vivo we analyzed gene expression profiles
from freshly isolated FH patient monocytes and from con-
trol monocytes using whole genome cRNA microarrays.
The gene expression profiles of FH monocytes were clearly
distinct from those of healthy individuals as demon-
strated by unsupervised principal component analysis.
Further, GO enrichment analyses pointed to an altered
vesicle transport from the plasma membrane to the lyso-
some. We identified two scavenger receptors, CD36 and
Lrp1 to be overexpressed in FH monocytes. CD36 has
been identified as one of the principal receptors for oxLDL
uptake by macrophages in mice [17,21]. The expression of
this receptor is largely restricted to lymphoid and haemat-
opoietic lineages, including monocytes, macrophages,
platelets and endothelial cells [22]. Blocking of CD36
uptake with an antibody resulted in a reduction of oxLDL
uptake by more than 50% which identified CD36 as the
major receptor for oxLDL in circulating monocytes from
FH patients and healthy controls. However, the total
amount of oxLDL uptake via CD36 clearly distinguishes
FH monocytes from control monocytes.
Although none of the homozygous FH patients who took
part in this study had a residual LDL-R activity of more
than 5 percent and LDL-R expression was slightly down-
regulated in these individuals (data not shown), we
observed a 50% higher nLDL uptake in FH monocytes.
This finding was surprising, as LDLR defective fibroblasts
do not take up nLDL. It indicates that FH monocytes have
an alternative uptake mechanism for nLDL not present in
FH fibroblasts. Although Lrp1 was shown to be a receptor
Increased CD36 and CD91/Lrp1 levels on the surface of monocytes from FH patients and their role in LDL uptake Figure 4
Increased CD36 and CD91/Lrp1 levels on the surface of monocytes from FH patients and their role in LDL 
uptake. A: Representative measurements by flow cytometry of the cell surface expression of CD36 and CD91/Lrp1 on mono-
cytes of a control (no filling), of a heterozygous FH patient (gray filling) and of a homozygous FH patient (black filling). One rep-
resentative measurement of an antibody isotype control is illustrated as a black dotted line. The y-axis shows the percentage of 
maximum events. B: Western Blot analysis of CD91/Lrp1 of four homozygous FH patients and four controls. β-actin was used 
as loading control. C: Monocytes of homozygous FH patients (black filled bars), heterozygous FH patients (grey filled bars) and 
control individuals (open bars) were incubated with CD36-blocking antibody FA6-152, control murine IgG or left untreated for 
0,5 h at 37°C; after incubation cells were incubated with 100 μg/ml AF647 labelled oxLDL for 4 h at 37°C. (homozygous FH n 
= 5,, heterozygous FH patients n = 4, healthy controls n = 5) D: Monocytes of homozygous FH patients (black filled bars), het-
erozygous FH patients (grey filled bars) and control individuals (open bars) were incubated with CD91/Lrp1-blocking antibody, 
control rabbit IgG or left untreated for 0,5 h at 37°C; after incubation cells were incubated with 100 μg/ml AF647 labelled 
nLDL for 4 h at 37°C. Experiments in C and D were done in duplicate. Histogram bars indicate the mean ± SD (** p < 0.01, *** 
p < 0.001).BMC Medical Genomics 2008, 1:60 http://www.biomedcentral.com/1755-8794/1/60
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for the binding and uptake of native LDL in peritoneal
and J774 macrophages [23,24], we found no participation
of this receptor in the uptake of nLDL by FH monocytes.
Llorente-Cortes et al. recently reported that in monocyte-
derived macrophages Lrp1-expression is regulated by
Srebf2, whereupon a down-regulation of Srebf2, due to
elevated intracellular cholesterol, results in a down-regu-
lation of the LDL receptor and in an up-regulation of Lrp1
which is in good concordance with our findings [25,26].
Although we cannot explain the mechanism for nLDL
uptake, macropinocytosis could be one possible explana-
tion, as it has recently been shown that this process con-
tributes to foam cell formation by the uptake of nLDL in
macrophages [27].
To prevent a cholesterol/lipid overload macrophages are
able to release excessive cholesterol via Npc1 mediated
transport to intracellular destinations and the subsequent
efflux of cholesterol to apo A1 via Abca1 [3]. Both pro-
teins were found down-regulated in FH monocytes, which
further contributes to the lipid overload of FH monocytes.
Studies regarding the function of oxLDL with respect to
ABCA1 transcription have indicated that in macrophages
oxysterols lead to the induction of ABCA1-expression via
LXR [28,29] which is different from our observation in FH
monocytes where expression of LXRα and LXRβ is
unchanged. However, Zhou et al recently reported that
LDLR deficiency impairs ABCA1 expression in macro-
phages via a SREBP dependent mechanism [20]. ABCA1
expression was also inhibited under oxysterol treatment
and its regulation was independent from LXRα and LXRβ
expression. They reported that LDLR is crucial in the regu-
lation of ABCA1 expression by inhibiting SREBP1 proteol-
ysis. Lack of LDLR led to abnormal SREBP response which
resulted in both, reduced ABCA1 expression and choles-
terol efflux [20]. This may explain the reduced ABCA1
expression observed in FH monocytes. Our observation of
an impaired ABCA1 gene expression in response to
human LDL receptor deficiency during differentiation of
FH monocytes into macrophages suggests that deranged
reverse cholesterol transport is a major contributor to
foam cell formation in FH. Furthermore, the lipid over-
load of FH monocytes is likely to cause the observed
down-regulation of the cholesterol sensitive SREBP2,
which is a positive regulator of ABCA1 transcription [30]
and thus can aid to further enhance ABCA1 repression. It
has been reported that ABCA1 is absent in cells of athero-
sclerotic lesions [31], which demonstrates that the tight
regulation of this efflux system is critical to atherosclerosis
development. Interestingly, INSIG2 and SCAP, which are
also members of the SREBP pathway that regulates intrac-
ellular cholesterol content [32], and the rate limiting
enzyme of the cholesterol de novo synthesis, HMGCR, are
down-regulated in FH monocytes as well. In addition,
intracellular lanosterol, a precursor of cholesterol in the de
novo biosynthesis pathway, was found to be decreased in
FH monocytes, further arguing for a cellular lipid over-
load caused by elevated lipid influx and reduced efflux.
In conclusion, we have demonstrated significant differ-
ences between circulating monocytes from patients with
FH and those from control persons. FH monocytes con-
tain larger amounts of lipids as evidenced by Oil Red O
staining. This finding can be explained by the observed
increased uptake of nLDL and oxLDL, which is accompa-
nied by a down-regulation of the SREBP pathway and its
target genes, and by a reduced level of intracellular lanos-
terol. Moreover, a down-regulation of key proteins of cho-
lesterol transport and cholesterol efflux was observed. The
increased uptake of oxLDL into FH monocytes was found
to be largely mediated by the scavenger receptor CD36.
We have identified processes that substantially alter the
metabolism of circulating monocytes in an extreme
hypercholesterolemic environment such as the blood
compartment in FH. These changes that lead to a lipid
overload of monocytes already in the circulation may pro-
mote the formation of local inflammatory sites that
favour the onset of atherosclerosis. The large numbers of
genes that are significantly altered in FH monocytes sug-
gest, however, that many as yet unidentified genes also
contribute to this process.
Competing interests
The authors declare that they have no competing interests.
Expression of NPC1 and ABCA1 in monocytes of FH  patients and of healthy control individuals Figure 5
Expression of NPC1 and ABCA1 in monocytes of FH 
patients and of healthy control individuals. A: qRT-PCR 
shows that mRNA expression of NPC1 is decreased in FH 
monocytes. B: Western Blot analysis of Npc1 and Abca1 in 
monocytes of three homozygous FH patients and three con-
trols. C: qRT-PCR analysis of ABCA1 expression fold change 
during differentiation of monocytes to macrophages over 10 
days of homozygous FH patients (n = 4) and healthy controls 
(n = 4). Histogram bars indicate the mean ± SD. Expression 
levels in control monocytes were compared with those of all 
FH carriers and with FH homozygotes only (* p < 0.05, ** p 
< 0.01).BMC Medical Genomics 2008, 1:60 http://www.biomedcentral.com/1755-8794/1/60
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